Publication details
Prevence cévních mozkových příhod léčbou hypolipidemiky
| Title in English | Hypolipidemic drugs in the prevention of Ischemic strokes |
|---|---|
| Authors | |
| Year of publication | 2010 |
| Type | Article in Periodical |
| Magazine / Source | Česká a slovenská neurologie a neurochirurgie |
| MU Faculty or unit | |
| Citation | |
| Field | Pharmacology and pharmaceutical chemistry |
| Keywords | cholesterol; ischemic stroke; statins; fibrates; niacin; ezetimibe; resins |
| Description | Hypolipidemic drugs, and statins in particular, are very important in the prevention of both primary and secondary coronary events. These drugs also play an important role in the prevention of ischemic stroke, despite the fact that their part in relative risk reduction for ischemic stroke is less than that of treatment with antiplatelet or anti hypertensive drugs. When considering the results of interventional studies, the statins gemfibrozil and nicotinic acid may be used for primary prevention of ischemic stroke. These drugs can decrease the risk of ischemic stroke in patients with dyslipidemia and coronary heart disease, but certain other statins (e.g. atorvastatin, rosuvastatin) can also decrease the risk of stroke in high-risk people without cardiovascular disease provided their LDL-cholesterol is above target level. Atorvastatin (80 mg a day) is the only hypolipidemic drug that has provided evidence for secondary prevention of ischemic stroke. When choosing a hypolipidemic drug for the prevention of stroke based on clinical studies, one should always consider which study population is involved and which drug has been used for the prevention of ischemic stroke. |